<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33340120</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial.</ArticleTitle><Pagination><StartPage>371</StartPage><EndPage>383</EndPage><MedlinePgn>371-383</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27146</ELocationID><Abstract><AbstractText Label="BACKGROUND">To collect preliminary data on the effects of mexiletine on cortical and axonal hyperexcitability in sporadic amyotrophic lateral sclerosis (ALS) in a phase 2 double-blind randomized controlled trial.</AbstractText><AbstractText Label="METHODS">Twenty ALS subjects were randomized to placebo and mexiletine 300 or 600&#x2009;mg daily for 4 wk and assessed by transcranial magnetic stimulation and axonal excitability studies. The primary endpoint was change in resting motor threshold (RMT).</AbstractText><AbstractText Label="RESULTS">RMT was unchanged with 4 wk of mexiletine (combined active therapies) as compared to placebo, which showed a significant increase (P = .039). Reductions of motor evoked potential (MEP) amplitude (P = .013) and accommodation half-time (P = .002), secondary outcome measures of cortical and axonal excitability, respectively, were also evident at 4 wk on mexiletine.</AbstractText><AbstractText Label="CONCLUSIONS">The relative stabilization of RMT in the treated subjects was unexpected and could be attributed to unaccounted sources of error or chance. However, a possible alternative cause is neuromodulation preventing an increase. The change in MEP amplitude and accommodation half-time supports the reduction of cortical and axonal hyperexcitability with mexiletine.</AbstractText><CopyrightInformation>&#xa9; 2020 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0003-4064-1032</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macklin</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIlduff</LastName><ForeName>Courtney E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vucic</LastName><ForeName>Steve</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Royal Prince Alfred Hospital; and the Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wainger</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Royal Prince Alfred Hospital; and the Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goutman</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0001-8780-6637</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goyal</LastName><ForeName>Namita A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Irvine, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutkove</LastName><ForeName>Seward B</ForeName><Initials>SB</Initials><Identifier Source="ORCID">0000-0002-6375-3312</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladha</LastName><ForeName>Shafeeq S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>I-Hweii Amy</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of South Carolina, Charleston, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harms</LastName><ForeName>Matthew B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brannagan</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacomis</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-8646-943X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zivkovic</LastName><ForeName>Sasha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Maxwell</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Leo H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-8574-5332</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Penn State University, Hershey, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivner</LastName><ForeName>Michael H</ForeName><Initials>MH</Initials><Identifier Source="ORCID">0000-0002-6135-035X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Augusta University, Augusta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shefner</LastName><ForeName>Jeremy M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atassi</LastName><ForeName>Nazem</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Mexiletine-2 ALS Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DP2 NS106664</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061567">Voltage-Gated Sodium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>1U511HHV4Z</RegistryNumber><NameOfSubstance UI="D008801">Mexiletine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="Y">Axons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071080" MajorTopicYN="Y">Cortical Excitability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004568" MajorTopicYN="N">Electrodiagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004576" MajorTopicYN="N">Electromyography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019054" MajorTopicYN="N">Evoked Potentials, Motor</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008475" MajorTopicYN="N">Median Nerve</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008801" MajorTopicYN="N">Mexiletine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009431" MajorTopicYN="N">Neural Conduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074286" MajorTopicYN="N">Preliminary Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050781" MajorTopicYN="N">Transcranial Magnetic Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061567" MajorTopicYN="N">Voltage-Gated Sodium Channel Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">axonal excitability</Keyword><Keyword MajorTopicYN="N">outcome research</Keyword><Keyword MajorTopicYN="N">randomized controlled clinical trial</Keyword><Keyword MajorTopicYN="N">transcranial magnetic stimulation</Keyword></KeywordList><CoiStatement>DISCLOSURES OF CONFLICTS OF INTEREST. Dr. Weiss has consulted for Ra Pharma, Argenx, and Biogen and is a speaker for NuFactor. Dr. Macklin is a DSMB member for Shire Human Genetic Therapies and for Novartis, a Steering Committee member for a Biogen trial, and on the advisory board member for Cerevance, Intrance, and Inventram, and has received research support from Amylyx Pharmaceuticals, GlaxoSmithKline, and Mitsubishi Tanabe Pharma America. Professor Vucic reports receiving funding from the National Health &amp; Medical Research Council Australia, honoraria from CSL Australia, and serving on scientific advisory boards for Biogen and ClENE. Dr. Wainger has received personal compensation from Amgen, Quralis, Apic Biosciences, Q-State Biosciences, Takeda, and is co-inventor on a patent for the use of potassium channel openers in neurodegenerative diseases. He is a New York Stem Cell Foundation&#x2013;Robertson Investigator and has received research funding from the ALS Association, GlaxoSmithKline, AI Therapeutics, Target ALS, NIH, Revalesio, and Sanofi. Dr. Goutman is on the scientific advisory for Biogen and IFT Pharma. Dr. Goyal has received research support from Brainstorm Cell Therapeutics, Cytokinetics, Fulcrum, Kezar, Novartis, Octapharma, Orion, Orphazyme, served on Advisory Boards for Acceleron, Alexion, Argenx, Biogen, CSL Behring, Cytokinetics, MT Pharma, Novartis, Sanofi Genzyme, Sarepta, and is on the speaker's bureau for CSL. Dr. Rutkove has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Myolex, Biogen, Axcella Health, Merck. He has received personal compensation in an editorial capacity for Annals of Neurology and for serving on the Board of Directors of Myolex, Inc. He also holds stock and/or stock options in Myolex, Inc. Dr. Ladha reports receiving research support from the ALS Association, consulting for Biogen and Amylyx, and speaking for Biogen. Dr. Chen reports research support from the Muscular Dystrophy Association, ALS Association/ Barrow Neurological Institute, Flex Pharma, Inc., Healey ALS Center, NEALS, UCB, and consulting for Biogen. Dr. Harms has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Sanofi, and Maze Therapeutics and received research support from Biogen. Dr. Brannagan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Grifols, Ionis, Akcea, Alnylam, Shire, and CSL Behring and research support from Ionis, Alnylam, Viromed, Catalyst, Pharnext, Flexpharma, Novartis, and Grifols. Dr. Lacomis reports research support from Orion Pharma, Mitsubishi-Tanabe, and the ALS Association, and royalties from UpToDate. Dr. Wang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen and Argenx. He also holds stock and/or stock options in GWPH and Spark Therapeutics and has received research support from Fulcrum Therapeutic. Dr. Simmons has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biohaven, Biogen, Cytokinetics. He has also received personal compensation in an editorial capacity for Muscle &amp; Nerve and research support from Biogen, Biohaven, Cytokinetics, Genzyme, and Mallinckrodt. Dr. Rivner has consulted for and received research support from Alexion and Allergan, Research support from UCB, Mallinckrodt, Cytokinetics, Momenta, Shire Takeda, Orion, Biohaven, Catalyst, Grifols, Seikagaku, and RA pharmaceuticals. Dr. Shefner has received personal compensation from Cytokinetics, Avexis, Revalasio, Biohaven, Neurosense, MTPA, and Otsuka and for serving as neuromuscular section editor for UpToDate, and research support from Cytokinetics, Biogen, Brainstorm, MTPA, and Amylyx. Dr. Cudkowicz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Takeda, Biogen, Cytokinetics, Sunovian, Immunitypharm, and Avexis. Dr. Atassi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, GSK, MT Pharma, and Neuropore Therapies. The remaining authors have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>19</Day><Hour>8</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33340120</ArticleId><ArticleId IdType="mid">NIHMS1744173</ArticleId><ArticleId IdType="pmc">PMC8513796</ArticleId><ArticleId IdType="doi">10.1002/mus.27146</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain. 2008;131:1540&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pubmed">18469020</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills K, Nithi K. Corticomotor threshold is reduced in early sporadic amyotrophic lateral sclerosis. Muscle Nerve. 1997;20:1137&#x2013;1141.</Citation><ArticleIdList><ArticleId IdType="pubmed">9270669</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziemann U, Winter M, Reimers CD, Reimers K, Tergau F, Paulus W. Impaired motor cortex inhibition in patients with amyotrophic lateral sclerosis. Evidence from paired transcranial magnetic stimulation. Neurology. 1997;49:1292&#x2013;1298.</Citation><ArticleIdList><ArticleId IdType="pubmed">9371911</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Evangelista T, Sales-Lu&#xed;s ML. The corticomotor threshold is not dependent on disease duration in amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3:39&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">12061947</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae JS, Simon NG, Menon P, Vucic S, Kiernan MC. The puzzling case of hyperexcitability in ALS. J Clin Neurol. 2013;9:65&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3633193</ArticleId><ArticleId IdType="pubmed">23626643</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai Y, Shibuya K, Misawa S, et al. Axonal dysfunction precedes motor neuronal death in amyotrophic lateral sclerosis. PLoS One. 2016;11(7):e0158596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4934877</ArticleId><ArticleId IdType="pubmed">27383069</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Kiernan MC. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain. 2006;129:2436&#x2013;2446.</Citation><ArticleIdList><ArticleId IdType="pubmed">16835248</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, Kiernan MC, Vucic S. Cortical dysfunction underlies the development of the split-hand in amyotrophic lateral sclerosis. PLoS One. 2014;9(1):e87124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3901749</ArticleId><ArticleId IdType="pubmed">24475241</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Kiernan MC. Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2007;78:849&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117729</ArticleId><ArticleId IdType="pubmed">17210625</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Kiernan MC. Utility of transcranial magnetic stimulation in delineating amyotrophic lateral sclerosis pathophysiology. Handb Clin Neurol. 2013;116:561&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pubmed">24112924</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, Geevasinga N, Yiannikas C, Howells J, Kiernan MC, Vucic S. Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurol. 2015;14(5):478&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">25843898</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, Higashihara M, van den Bos M, Geevasinga N, Kiernan MC, Vucic S. Cortical hyperexcitability evolves with disease progression in ALS. Ann Clin Transl Neurol. 2020;7(5):733&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7261748</ArticleId><ArticleId IdType="pubmed">32304186</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, Kiernan MC, Vucic S. Cortical hyperexcitability precedes lower motor neuron dysfunction in ALS. Clin Neurophysiol. 2015;126(4):803&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">25227219</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya K, Park SB, Geevasinga N, et al. Motor cortical function determines prognosis in sporadic ALS. Neurology. 2016;87(5):513&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">27402895</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, Menon P, Howells J, Nicholson GA, Kiernan MC, Vucic S. Axonal ion channel dysfunction in c9orf72 familial amyotrophic lateral sclerosis. JAMA Neurol. 2015;72(1):49&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">25384182</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Kiernan MC. Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol. 2006;117(7):1458&#x2013;1466.</Citation><ArticleIdList><ArticleId IdType="pubmed">16759905</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya K, Misawa S, Nasu S, et al. Split hand syndrome in amyotrophic lateral sclerosis: different excitability changes in the thenar and hypothenar motor axons. J Neurol Neurosurg Psychiatry. 2013;84(9):969&#x2013;972.</Citation><ArticleIdList><ArticleId IdType="pubmed">23467416</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Kiernan MC. Upregulation of persistent sodium conductances in familial ALS. J Neurol Neurosurg Psychiatry. 2010;81(2):222&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">19726402</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai K, Kuwabara S, Misawa S, et al. Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage. Brain. 2006;129:953&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pubmed">16467388</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai K, Shibuya K, Sato Y, et al. Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(7):734&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">22566594</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritz E, Izaurieta P, Weiss A, et al. Mutant SOD1-expressing astrocytes release toxic factors that trigger motoneuron death by inducing hyperexcitability. J Neurophysiol. 2013;109(11):2803&#x2013;2814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3680799</ArticleId><ArticleId IdType="pubmed">23486205</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai K, Kuwabara S, Arai K, Sung JY, Ogawara K, Hattori T. Muscle cramp in Machado-Joseph disease: altered motor axonal excitability properties and mexiletine treatment. Brain. 2003;126:965&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">12615652</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss MD, Macklin EA, Simmons Z, et al. Mexiletine ALS study group. A randomized trial of mexiletine in ALS: safety and effects on muscle cramps and progression. Neurology. 2016;86(16):1474&#x2013;1481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4836879</ArticleId><ArticleId IdType="pubmed">26911633</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on motor neuron diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Bostock H, Cikurel K, Burke D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve. 1998;21:137&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">9466589</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Burke D, Andersen KV, Bostock H. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve. 2000;23:399&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">10679717</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke D, Kiernan MC, Bostock H. Excitability of human axons. Clin Neurophysiol. 2001;112:1575&#x2013;1585.</Citation><ArticleIdList><ArticleId IdType="pubmed">11514239</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankelowitz SK, Burke D. Axonal excitability in the forearm: normal data and differences along the median nerve. Clin Neurophysiol. 2009;120(1):167&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">19028441</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermsen AM, Haag A, Duddek C, et al. Test-retest reliability of single and paired pulse transcranial magnetic stimulation parameters in healthy subjects. J Neurol Sci. 2016;362:209&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">26944150</ArticleId></ArticleIdList></Reference><Reference><Citation>Hays RD, Sherbourne CD, Mazel RM. The RAND 36-item health survey 1.0. Health Econ. 1993;2(3):217&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">8275167</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Moore D, Mozaffar T, et al. Mexiletine for muscle cramps in amyotrophic lateral sclerosis: a randomized, double-blind crossover trial. Muscle Nerve. 2018;58(1):42&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6126993</ArticleId><ArticleId IdType="pubmed">29510461</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Ziemann U, Eisen A, Hallett M, Kiernan MC. Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. J Neurol Neurosurg Psychiatry. 2013;84(10):1161&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786661</ArticleId><ArticleId IdType="pubmed">23264687</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Cikurel K, Bostock H. Effects of temperature on the excitability properties of human motor axons. Brain. 2001;124(Pt 4):816&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">11287380</ArticleId></ArticleIdList></Reference><Reference><Citation>Chervyakov AV, Bakulin IS, Savitskaya NG, et al. Navigated transcranial magnetic stimulation in amyotrophic lateral sclerosis. Muscle Nerve. 2015;51(1):125&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">25049055</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanette G, Tamburin S, Manganotti P, Refatti N, Forgione A, Rizzuto N. Changes in motor cortex inhibition over time in patients with amyotrophic lateral sclerosis. J Neurol. 2002;249(12):1723&#x2013;1728.</Citation><ArticleIdList><ArticleId IdType="pubmed">12529797</ArticleId></ArticleIdList></Reference><Reference><Citation>Schanz O, Bageac D, Braun L, Traynor BJ, Lehky TJ, Floeter MK. Cortical hyperexcitability in patients with C9ORF72 mutations: relationship to phenotype. Muscle Nerve. 2016;54(2):264&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4940214</ArticleId><ArticleId IdType="pubmed">26799151</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh W, Dharmadasa T, Vucic S, Kiernan MC. Functional biomarkers for amyotrophic lateral sclerosis. Front Neurol. 2019;9:1141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6328463</ArticleId><ArticleId IdType="pubmed">30662429</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, Menon P, Sue CM, et al. Cortical excitability changes distinguish the motor neuron disease phenotypes from hereditary spastic paraplegia. Eur J Neurol. 2015;22(5):826&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pubmed">25683471</ArticleId></ArticleIdList></Reference><Reference><Citation>Pohl C, Block W, Tr&#xe4;ber F, et al. Proton magnetic resonance spectroscopy and transcranial magnetic stimulation for the detection of upper motor neuron degeneration in ALS patients. J Neurol Sci. 2001;190(1&#x2013;2):21&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">11574102</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulus W, Classen J, Cohen LG, et al. State of the art: pharmacologic effects on cortical excitability measures tested by transcranial magnetic stimulation. Brain Stimul. 2008;1(3):151&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">20633382</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger BJ, Kiskinis E, Mellin C, et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014;7(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4023477</ArticleId><ArticleId IdType="pubmed">24703839</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Masson G, Przedborski S, Abbott LF. A computational model of motor neuron degeneration. Neuron. 2014;83(4):975&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4167823</ArticleId><ArticleId IdType="pubmed">25088365</ArticleId></ArticleIdList></Reference><Reference><Citation>Uebachs M, Opitz T, Royeck M, et al. Efficacy loss of the anticonvulsant carbamazepine in mice lacking sodium channel beta subunits via paradoxical effects on persistent sodium currents. J Neurosci. 2010;30(25):8489&#x2013;8501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6634624</ArticleId><ArticleId IdType="pubmed">20573896</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Cheah BC, Yiannikas C, Kiernan MC. Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol. 2011;122(9):1860&#x2013;1866.</Citation><ArticleIdList><ArticleId IdType="pubmed">21382747</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, Menon P, Nicholson GA, et al. Cortical function in asymptomatic carriers and patients with C9orf72 amyotrophic lateral sclerosis. JAMA Neurol. 2015;72(11):1268&#x2013;1274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707047</ArticleId><ArticleId IdType="pubmed">26348842</ArticleId></ArticleIdList></Reference><Reference><Citation>Howells J, Czesnik D, Trevillion L, Burke D. Excitability and the safety margin in human axons during hypothermia. J Physiol. 2013;591(12):3063&#x2013;3080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3832120</ArticleId><ArticleId IdType="pubmed">23613528</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya K, Misawa S, Kimura H, et al. A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: efficacy and safety of sodium channel blocker phase II trial. Amyotrophic Lateral Scler Frontotemporal Degener. 2015;16(5&#x2013;6):353&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">25960085</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>